Tags

Type your tag names separated by a space and hit enter

Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Clin Infect Dis. 2000 Oct; 31(4):1110-3.CI

Abstract

A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.

Authors+Show Affiliations

The Kala-Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India. shyams@nde.vsnl.net.inNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11049800

Citation

Sundar, S, et al. "Short-course of Oral Miltefosine for Treatment of Visceral Leishmaniasis." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 31, no. 4, 2000, pp. 1110-3.
Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis. 2000;31(4):1110-3.
Sundar, S., Makharia, A., More, D. K., Agrawal, G., Voss, A., Fischer, C., Bachmann, P., & Murray, H. W. (2000). Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 31(4), 1110-3.
Sundar S, et al. Short-course of Oral Miltefosine for Treatment of Visceral Leishmaniasis. Clin Infect Dis. 2000;31(4):1110-3. PubMed PMID: 11049800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-course of oral miltefosine for treatment of visceral leishmaniasis. AU - Sundar,S, AU - Makharia,A, AU - More,D K, AU - Agrawal,G, AU - Voss,A, AU - Fischer,C, AU - Bachmann,P, AU - Murray,H W, PY - 2000/10/26/pubmed PY - 2001/3/3/medline PY - 2000/10/26/entrez SP - 1110 EP - 3 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 31 IS - 4 N2 - A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/11049800/Short_course_of_oral_miltefosine_for_treatment_of_visceral_leishmaniasis_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/318122 DB - PRIME DP - Unbound Medicine ER -